This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Tool
  2. Source: Campus Sanofi
  3. 3 Feb 2025
5 min

Eczema Area and Severity Index (EASI)

Author: Sanofi

People speaking

DUPIXENT(dupilumab) Prescribing Information UK

The American EASI (Eczema Area and Severity Index) score was developed from the PASI (Psoriasis Area and Severity Index) score used for psoriasis and published in 2001.1, 2

The EASI assesses the extent of eczema in 4 specific areas of the body (head/neck, torso, arms/legs) and measures the severity of 4 clinical signs (erythema, induration/papules, excoriation, lichenification).1-3

The score ranges from 0 to 72 (most impaired state) and also sets out the strata of AD severity:1, 2

Atopic dermatitis

Mild

Moderate

Severe

Score EASI

1-7

8-21

>21

References

  1. Hanifin JM, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-8.

  2. Rehal B, et al. Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985-2010. PLoS One. 2011;13:6(4):e17520.

  3. Gooderham MJ, et al Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: Tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018; 22(1_suppl), 10S-16S.

  4. Images supplied by Dr Esther Serra, Sant Pau i Santa Creu Hospital, Barcelona, and from the Sanofi and Regeneron patient photo catalogue.

Photo of the paper ADCT test

Atopic Dermatitis Control Test (ADCT)

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

Try the ADCT

MAT-XU-2304531 (v1.0) Date of Preparation: February 2025